Figure 2.

Optimizing MS-OVA treatment. C57BL/6 mice were given 10⁶ B16-OVA tumor cells s.c. in the dorsal flank, MS-OVA was given s.c. at the base of the tail on (A), day 3 and 24 or (B) day 3 and 8, and tumor growth was measured over time. Alternatively, a reduced number of tumor cells, 10⁵ of B16-OVA, were injected followed by MS-OVA treatment on (C) day 3 and 8, (D) day 3, or day 3, 10 and 29, and tumor growth was measured. The mean frequency ± SD of OVA-CD8⁺ T cells was compared in mice treated with MS-OVA on day 3 vs. days 3, 10, and 29 (E).